CytRx Corporation (CYTR): Price and Financial Metrics
GET POWR RATINGS... FREE!
CYTR Stock Price Chart Interactive Chart >
CYTR Price/Volume Stats
| Current price | $0.14 | 52-week high | $4.70 |
| Prev. close | $0.14 | 52-week low | $0.09 |
| Day low | $0.13 | Volume | 14,700 |
| Day high | $0.14 | Avg. volume | 132,593 |
| 50-day MA | $0.20 | Dividend yield | N/A |
| 200-day MA | $0.47 | Market Cap | 6.09M |
CytRx Corporation (CYTR) Company Bio
CytRx Corporation operates as a biopharmaceutical research and development company specializing in oncology. The company was founded in 1985 and is based in Los Angeles, California.
Latest CYTR News From Around the Web
Below are the latest news stories about Cytrx Corp that investors may wish to consider to help them evaluate CYTR as an investment opportunity.
CytRx Comments on Orphazyme's Update on European Union Regulatory Review of Arimoclomol in Niemann-Pick Disease Type CLOS ANGELES, February 24, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today commented on Orphazyme A/S's (NASDAQ: ORPH) ("Orphazyme") announced update on the ongoing review of the Marketing Authorisation Application for its investigational product candidate, arimoclomol, for the treatment of Niemann-Pick disease type C ("NPC") by the Committee for Medic |
CytRx Highlights Orphazyme's Update on Planned NDA Resubmission for Arimoclomol in Niemann-Pick Disease Type CLOS ANGELES, February 14, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today highlighted Orphazyme A/S's (NASDAQ: ORPH) ("Orphazyme") announced update on the process and anticipated timelines for resubmission of its New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") for its investigational product candidate, arimoclomol, for th |
CytRx to Hold Town Hall for Stockholders on Thursday, January 20thLOS ANGELES, January 18, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that it will hold a town hall for stockholders on Thursday, January 20, 2022 at 4:30 PM Eastern. The town hall will be led by the Company’s Chief Executive Officer, Dr. Stephen Snowdy, and include a question-and-answer session. The town hall can be accessed |
CytRx to Participate in the H.C. Wainwright BioConnect Virtual ConferenceLOS ANGELES, January 07, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that John Caloz, the Company’s Chief Financial Officer, is scheduled to present at the H.C. Wainwright BioConnect Virtual Conference, which is taking place virtually from Monday, January 10th through Thursday, January 13th. |
CytRx Announces the Appointment of Dr. Stephen Snowdy as Chief Executive OfficerLOS ANGELES, January 03, 2022--CytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development in oncology and neurodegenerative diseases, today announced that it has appointed Dr. Stephen Snowdy to the role of Chief Executive Officer, effective January 10, 2022. Dr. Louis Ignarro succeeded Steven A. Kriegsman as Chairman of the Board of Directors (the "Board") on January 3, 2022. |
CYTR Price Returns
| 1-mo | 12.00% |
| 3-mo | -70.83% |
| 6-mo | -76.66% |
| 1-year | -91.19% |
| 3-year | -75.00% |
| 5-year | -96.80% |
| YTD | -72.28% |
| 2021 | -71.14% |
| 2020 | 503.45% |
| 2019 | -35.56% |
| 2018 | -73.37% |
| 2017 | -23.87% |
Loading social stream, please wait...